Ebola Symptoms

Understanding the Two-Phase Progression: What the Clinical Picture Actually Means

The "dry phase / wet phase" framework described above is more than a clinical mnemonic — it reflects a biological progression with direct implications for transmission risk, treatment timing, and survival. The early-phase symptoms listed in the first card (fever, headache, fatigue, sore throat) are nonspecific. They could represent malaria, typhoid, cholera, or a dozen other conditions endemic to the same regions where Ebola circulates. This diagnostic overlap is one reason why exposure history — not symptoms alone — is the critical triage question. As the WHO fact sheet and Jacob et al. (2020) both note, the early phase is also when a patient may be least severely ill and most mobile, which is precisely the window when isolation protocols matter most.

The transition to the wet phase — marked by vomiting, diarrhea, and in some patients bleeding — represents a shift in both disease severity and transmission risk. The virus-laden body fluids produced during this phase are the primary vehicle for person-to-person spread, which is why healthcare-associated transmission and funeral-associated transmission dominate outbreak case counts. Jacob et al. (2020) in Nature Reviews Disease Primers — cited below — provides detailed mechanistic analysis of how Ebola targets endothelial cells and suppresses the interferon response, leaving patients unable to mount a normal antiviral defense while vascular integrity deteriorates.

The FAQ entry on fatality rates correctly notes that modern antivirals (mAb114 and REGN-EB3) have substantially improved survival. What the numbers don't fully convey is how rapidly that improvement came: the PALM RCT, published in The New England Journal of Medicine in 2019 (cited below), found that REGN-EB3 (atoltivimab/maftivimab/odesivimab) reduced 28-day mortality from approximately 49% in the control arm to approximately 33%. For patients treated early — at lower viral loads — the survival benefit was even more pronounced. The implication is that the window between symptom onset and presentation to care matters enormously, which connects directly to the monitoring and isolation protocols outlined in the CDC and WHO sources cited on this page.

The FAQ note that Ebola is not contagious during the incubation period distinguishes it sharply from respiratory viruses like SARS-CoV-2, where pre-symptomatic transmission drives exponential spread. Ebola's requirement for direct contact with symptomatic body fluids is what makes it so deadly within clinical and household settings — and what prevents it from spreading with the geographic reach of airborne pathogens. Understanding this asymmetry — highly lethal within exposure chains, but geographically containable if those chains are identified and interrupted — is essential context for interpreting outbreak risk. This analysis is for informational purposes only and does not constitute medical advice. If you believe you have been exposed to Ebola, contact a healthcare provider or emergency services immediately.